Semler Scientific to Present at Upcoming Investor Conferences
Semler Scientific, Inc. (SMLR) announced CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg's participation in several virtual investor conferences in September 2021. The events include the Colliers 2021 Institutional Investor Conference on September 9, H.C. Wainwright & Co. 23rd Annual Global Investment Conference on September 13, and the 2021 Best Ideas Growth (BIG5) Conference on September 14-15. Semler provides technology solutions to enhance healthcare provider effectiveness and offers the QuantaFlo® test for diagnosing peripheral arterial disease.
- None.
- None.
SANTA CLARA, Calif., Aug. 26, 2021 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that Chief Executive Officer Doug Murphy-Chutorian, M.D. and Chief Marketing Officer Dennis Rosenberg will participate in the following investor conferences that are being held virtually in September.
Colliers 2021 Institutional Investor Conference
Date: September 9, 2021
Format: One-on-one investor meetings
H.C. Wainwright & Co. 23rd Annual Global Investment Conference
Date: September 13, 2021
Format: On-demand corporate presentation is available beginning at 7:00 AM ET on September 13, 2021; one-on-one meetings. The webcast of the presentation will be archived for 90 days and may be accessed through the following link: https://journey.ct.events/view/557ff96b-03cc-487d-a12a-85504df11403.
2021 Best Ideas Growth (BIG5) Conference hosted by Lake Street Securities
Date: September 14 & 15, 2021
Format: One-on-one meetings
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific's mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific commercially launched its first patented and U.S. Food and Drug Administration, or FDA, cleared product in 2011, and received FDA 510(k) clearance for QuantaFlo®, the next generation version of this product, in 2015. QuantaFlo® is a rapid point-of-care test that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. QuantaFlo® is used by Semler Scientific's customers to more comprehensively evaluate their patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at semlerscientific.com.
INVESTOR CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650
View original content:https://www.prnewswire.com/news-releases/semler-scientific-to-present-at-upcoming-investor-conferences-301363322.html
SOURCE Semler Scientific, Inc.
FAQ
When will Semler Scientific present at the Colliers 2021 Institutional Investor Conference?
What format will the H.C. Wainwright & Co. 23rd Annual Global Investment Conference take?
What is the purpose of Semler Scientific's upcoming investor conferences?
What is the innovative product offered by Semler Scientific?
What is the stock symbol for Semler Scientific?
